Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28819044 | 0.88 | PROKR1 (0.47) | PROKR1 | |
| SCHEMBL4776483 | 0.84 | CYP1A2 (0.46) | PROKR1LMNA | |
| SCHEMBL26988715 | 0.78 | MAPT (0.42) | PROKR1 | |
| SCHEMBL11340185 | 0.76 | KDM4E (0.55) | PROKR1 | |
| SCHEMBL11099112 | 0.76 | PROKR1 (0.46) | PROKR1 | |
| SCHEMBL4776739 | 0.76 | MEN1 (0.40) | — | |
| SCHEMBL4915515 | 0.76 | HPGDS (0.39) | — | |
| SCHEMBL3927686 | 0.76 | LMNA (0.42) | PROKR1LMNA | |
| SCHEMBL4776611 | 0.75 | KCNK3 (0.45) | PROKR1LMNA | |
| SCHEMBL4306410 | 0.75 | PROKR1 (0.45) | PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | PROKR1 2194/4885LMNA 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.